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Abstract. Theworld is currently facing a novel COVID-19 pandemic caused by SARS-CoV-2 that, as of July 12, 2020,
has caused a reported 12,322,395 cases and 556,335 deaths. To date, only two treatments, remdesivir and dexa-
methasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients. The
search for new or repurposed drugs for treatment of COVID-19 continues. We have witnessed anecdotal use of herbal
medicines, includingArtemisia spp. extracts, in low-income countries, and exaggerated claims of their efficacies that are
not evidence based, with subsequent political controversy. These events highlight the urgent need for further research on
herbal compounds to evaluate efficacy through RCTs, and, when efficacious compounds are identified, to establish the
active ingredients, develop formulations and dosing, and define pharmacokinetics, toxicology, and safety to enable drug
development. Derivatives from the herb Artemisia annua have been used as traditional medicine over centuries for the
treatment of fevers, malaria, and respiratory tract infections. We review the bioactive compounds, pharmacological and
immunological effects, and traditional uses for Artemisia spp. derivatives, and discuss the challenges and controversies
surrounding current efforts and the scientific road map to advance them to prevent or treat COVID-19.
INTRODUCTION
The unprecedented COVID-19 pandemic caused by the
novel zoonotic pathogen of humans, SARS-CoV-2, has, as of
July 12, 2020, caused 556,335 deaths of 12,322,395 con-
firmed cases reported by the WHO.1 Although COVID-19
commonly presents as a severe respiratory tract illness, it
causes multisystem disease, and deaths have been attributed
to cytokine storm, acute respiratory distress syndrome (ARDS),
and excessive aberrant immunological responses. Of several
recent and ongoing treatment intervention trials, only two ran-
domized controlled trials have to date demonstratedbenefits of
specific therapies. One study indicated that hospitalized
COVID-19 patients who received remdesivir had a 31% faster
time to recovery than those who received placebo.2 Another
trial reported that dexamethasone reduced mortality by one-
third in seriously ill patients requiring respiratory support.3 Of
note, dexamethasone was previously shown to be effective in
the treatment of ARDS.4 Among other drugs initially considered
of promise, trials of chloroquine or hydroxycholoroquine plus
lopinavir/ritonavir with or without azithromycin have shown no
reduction in mortality in hospitalized patients.5
Despite limited success in finding effective treatments
7 months after the first appearance of SARS-CoV-2 as a new
human pathogen, the desperate quest for new and repur-
posed drugs to reduce the morbidity and mortality of COVID-
19 continues. The anecdotal use ofArtemisia spp. extracts for
COVID-19 treatment in low-income countries has led to ex-
aggerated and unproven claims of its efficacy in the absence
of a scientificbasis or results fromclinical trials. This highlights
the urgent need for further research on herbal compounds to
evaluate efficacy through controlled trials, and for efficacious
compounds, to establish the active ingredients, develop formu-
lations and dosing, and define pharmacokinetics, toxicology,
andsafety toenabledrugdevelopment.Wediscuss thebioactive
compounds, pharmacological and immunological effects, and
traditional uses for Artemisia spp. derivatives, and discuss the
challenges and controversies surrounding current efforts to ad-
vance them for potential use to prevent or treat COVID-19.
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PLANT-DERIVED MEDICINAL PRODUCTS FOR COVID-
19 MANAGEMENT?
Traditional herb- and plant-derived medicinal products are
being used and trialed for the treatment of COVID-19 in China.6,7
Amongmany, derivatives from the herbArtemisia annua (Figure 1)
have been used as traditional medicine over centuries for the
treatment of fevers, malaria, and respiratory tract infections.8 The
“sweet wormwood” plant contains artemisinin (Figure 2), a medi-
cine developed during the cultural revolution in China. The 2015
Nobel Prize in Physiology or Medicine was awarded to Professor
Youyou Tu for her key contributions to its discovery.9 The WHO
recommends artemisinin-based combination therapies (ACTs) as
first-line treatments for uncomplicated Plasmodium falciparum
malaria.10 Results of a small clinical study from China of artesu-
nate, a hemi-synthetic derivative of artemisinin (Figure 2), for the
treatment of COVID-19 reported that artesunate was associated
with shorter duration of COVID-19 symptoms (3.3 ± 1.9 versus
4.8±2.2days)andhospital stays (16.6±3.7versus18.0±4.0) than
standardof care.8 Table 1shows theconcentrationsof artemisinin
and artesunate that can be achieved in the plasma of patients
receiving conventional doses of these drugs, and the concentra-
tions needed to inhibit the replication of other viruses or the in-
flammatory response in vitro. These data suggest that artesunate
may offer both antiviral and anti-inflammatory effects at clinically
achievable concentrations.8,11,12
In April 2020, an herbal tonic derived fromA. annua extracts
by theMadagascar Institute of AppliedResearch and branded
“COVID-Organics” was launched. COVID-Organics has been
promoted as a cure for COVID-19. However, reliable phar-
macological and efficacy data are lacking, and there is con-
cern that its widespread use for COVID-19 could result in
reduced access to effective medicines as well as possible selection of P. falciparum resistance to ACTs by exposing
patients to suboptimal concentrations of artemisinin when
malaria cases are misdiagnosed as COVID-19. Of note, the
content of artemisinin in A. annua is about 1%, which means
that 50 g of plant material is needed to obtain the equivalent of
a 500-mg therapeutic dose of artemisinin, if considering a
100% extraction.13 Furthermore, the typical concentration of
artemisinin in infusions is around 50 mg/L; 10 L must be
ingested to absorb the antimalarial therapeutic dose, which is
not feasible. Therefore, to avoid the promotion of unproven
remedies in this climate of uncertainty and fear, it is important
that research into traditional medicinal plants and their deriv-
atives be conducted properly.
ARTEMISIA ANNUA AND BIOACTIVE COMPOUNDS
Artemisia annua is an annual herbaceous plant of the
Asteraceae family native to Asia and Eastern Europe
(Figure 1).14 As A. annua is the source for leading WHO-
approved antimalarials, seed varieties have been adapted by
breeding for lower latitudes, and cultivation has been suc-
cessfully achieved in many tropical countries.15 Artemisia
annua is a source ofmany biologically active compounds,16,17
with more than 220 compounds isolated and identified,18 in-
cluding at least 28 monoterpenes, 30 sesquiterpenes, 12 tri-
terpenoids and steroids, 36 flavonoids, seven coumarins, and
four aromatic and nine aliphatic compounds.15 It naturally
produces and stores artemisinin in the glandular trichomes
on its leaves, stems, and flowers.19 Sesquiterpenes, car-
yophyllene oxide, caryophyllene, farnesene, and germacreneFIGURE 1. Artemisia annua.
FIGURE 2. 2D and 3D chemical structures of artemisinin and arte-
sunate. In the 3D structure, carbon atoms appear as gray balls, hy-
drogen atoms as white balls, and oxygen atoms as red balls.
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D are the most abundant chemicals identified in the essential
oil of the fruits.20 Artemisinin is a sesquiterpene lactone,
containing an unusual endoperoxide group (Figure 2) which is
believed to be responsible for its antimalarial activity.
ARTEMISIA SPP. PRODUCTS-ANTI-INFLAMMATORY AND
IMMUNOMODULATORY EFFECTS AND COVID-19
TREATMENT POTENTIAL
Artemisia annua extracts are said to contain anti-
inflammatory, antioxidant, and antimicrobial substances,
and to show antiviral activity.21–23 The flavonoids casticin
and chrysosplenol D, extracted from A. annua, suppressed
the expression of inflammatory mediators through the reg-
ulation of NF-κB and c-JUN in amurinemacrophage cell line,
suggesting that these components might be useful in the
treatment of inflammatory and infectious disorders.24 The
water-soluble fraction of A. annua, after the extraction of
artemisinin, was shown to regulate the expression of pro-
inflammatory cytokines, matrix metalloproteinases, and NF-
κB; promote cell cycle arrest; drive reactive oxygen species
production; and induceBakorBax-dependent or independent
apoptosis.8 Artemisia annua extracts significantly inhibited
cytopathy caused by SARS-CoV strain BJ00125 and showed
activity against SARS-CoV-2 in Vero-E6 cell-based cyto-
pathic effect screening.26
ANECDOTAL USE OF A. ANNUA PRODUCTS FOR COVID-
19 TREATMENT
Since the beginning of the COVID-19 pandemic, formula-
tions of A. annua have been used in Africa and China for
COVID-19 prevention and treatment. In the DRC, herbal for-
mulations have been used for the prevention and treatment of
COVID-19 by fumigation, infusion, or decoction.27 It is im-
portant to emphasize that there are no controlled data sup-
porting the use of any of these, and their efficacy forCOVID-19
is unknown. Arguably, natural product research is only rele-
vant to the development of new drugs as a first step to iden-
tifying specific molecules with activity. Teas cannot function
as drugs meeting international standards, as their compo-
nents are unknown and not standardized.28 Advancing tradi-
tionalmedicineswill require identification of active components
of plant extracts, methods to yield purified compounds, and
determination of compound pharmacology including studies
of biological activity, bioavailability, absorption, distribution,
metabolism, excretion, and toxicity properties of each mole-
cule.28 For evaluation of the antiviral effects of herbal formu-
lations, the screening system should meet all requirements of
any good assay, including validity, lack of ambiguity, accu-
racy, reproducibility, simplicity, and reasonable cost. Because
these requirements are better met by in vitro screening, in vitro
bioassays must be used to guide the isolation of active com-
pounds from plant extracts. The antiviral activities of the pure
compounds must then be confirmed at a later stage by in vivo
assays in appropriate animal models.23
ROAD MAP FOR ARTEMISIA SPP. DERIVATIVES AS A
POTENTIAL THERAPEUTIC FOR COVID-19
The WHO acknowledges that the quantity and quality of
safety and efficacy data on traditional medicines are far from
sufficient to meet the criteria needed to support their use. The
reasons for the lack of research data include inadequate
healthcare policies and a lack of accepted research method-
ology for evaluating traditional medicines.8,26,29 At a time
when countries are consumed by their own national interests
and agendas, the world is looking to natural products to pro-
vide readily available, affordable treatments. A cure or treat-
ment for COVID-19 derived from locally grown herbs and
plants remains a viable option for some countries and com-
munities. However, to develop drugs rather than crude prep-
arations of herbs and plants, the specific pharmacologically
active components need to be isolated, verified through
proper pharmacological evaluation, and then possibly opti-
mized through modern (hemi) synthesis strategies before
being developed according to rigorous international guide-
lines for drugdevelopment. However, repurposing of available
plant-based drugs, for example, artesunate, offers a poten-
tial time- and cost-saving approach. Indeed, investigators
from Saudi Arabia have registered a placebo-controlled trial
(www.ClinicalTrials.gov Identifier: NCT04387240) to evaluate the
efficacyofartesunate inadultswithmildsymptomsofCOVID-19.
CONCLUSION
As the world desperately searches for new treatments to re-
duce rates of severemorbidity andmortality fromCOVID-19, the
promotion of new drug discovery building on extracts from tra-
ditional medicinal plants should be encouraged. The anecdotal
and unproven use of A. Annua for COVID-19 following claims
frompoliticiansandothers in low-incomecountrieshighlights the
need for hard data to establish the active ingredients; develop
formulations and dosing; define the pharmacokinetics, toxicol-
ogy, and safety; and evaluate efficacy through controlled trials.
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